TY - JOUR
T1 - A pilot study evaluating the safety of vaginal administration of a multi-particulate pellet formulation
AU - Santiago, Guido Lopes dos Santos
AU - Verstraelen, Hans
AU - Poelvoorde, Nele
AU - Corte, Steven De
AU - Claeys, Geert
AU - Trog, Marijke
AU - Backer, Ellen De
AU - Saerens, Bart
AU - Vervaet, Chris
AU - Boeck, Fabienne De
AU - Bortel, Lucas Van
AU - Remon, Jean Paul
AU - Temmerman, Marleen
AU - Vaneechoutte, Mario
AU - Verhelst, Rita
N1 - Funding Information:
This study was funded by a Grant from the Institute for the Promotion of Innovation by Science and Technology (IWT), Flanders, Belgium.
PY - 2009/11
Y1 - 2009/11
N2 - Aim: Quantitative evaluation of the effect caused by vaginal administration of gelatin capsules loaded with starch pellets and lyophilized powder, respectively, on vaginal pH and microflora. Method: Administration of gelatin capsules loaded with fast-disintegrating starch pellets (group P) or lyophilized lactose/skimmed milk (group L) was compared to no intervention (group C) in a 3-way randomized, double-blinded, parallel study with 18 volunteers. Follow-up visits were at day 6 (immediately after administration), day 14 (pill stop), day 22 (after withdrawal bleeding) and day 35 (midcycle). Vaginal pH was measured and swabs were taken for Gram staining and culture to assess the presence of hydrogen peroxide-producing lactobacilli. Colposcopy was performed to assess the occurrence of adverse effects on the vaginal and ectocervical mucosa. Results: No severe adverse events occurred. For all women, vaginal pH and Gram stain were normal from screening until pill stop. Although immediately after withdrawal bleeding, 8 out of 18 women had an elevated pH, a disturbed microflora or lacked hydrogen peroxide-producing lactobacilli, all women had hydrogen peroxide-producing lactobacilli and a normal vaginal pH at midcycle, and all but two had a normal Gram stain. Conclusion: No major differences could be observed between the groups, whereby all changes in pH and microflora could be ascribed to withdrawal bleeding, indicating that gelatin capsules, starch pellets and lyophilized powder are acceptable carrier materials for the vaginal delivery of probiotic strains.
AB - Aim: Quantitative evaluation of the effect caused by vaginal administration of gelatin capsules loaded with starch pellets and lyophilized powder, respectively, on vaginal pH and microflora. Method: Administration of gelatin capsules loaded with fast-disintegrating starch pellets (group P) or lyophilized lactose/skimmed milk (group L) was compared to no intervention (group C) in a 3-way randomized, double-blinded, parallel study with 18 volunteers. Follow-up visits were at day 6 (immediately after administration), day 14 (pill stop), day 22 (after withdrawal bleeding) and day 35 (midcycle). Vaginal pH was measured and swabs were taken for Gram staining and culture to assess the presence of hydrogen peroxide-producing lactobacilli. Colposcopy was performed to assess the occurrence of adverse effects on the vaginal and ectocervical mucosa. Results: No severe adverse events occurred. For all women, vaginal pH and Gram stain were normal from screening until pill stop. Although immediately after withdrawal bleeding, 8 out of 18 women had an elevated pH, a disturbed microflora or lacked hydrogen peroxide-producing lactobacilli, all women had hydrogen peroxide-producing lactobacilli and a normal vaginal pH at midcycle, and all but two had a normal Gram stain. Conclusion: No major differences could be observed between the groups, whereby all changes in pH and microflora could be ascribed to withdrawal bleeding, indicating that gelatin capsules, starch pellets and lyophilized powder are acceptable carrier materials for the vaginal delivery of probiotic strains.
KW - Bacterial vaginosis
KW - Pellet
KW - Probiotics
KW - Starch
KW - Vaginal delivery
UR - http://www.scopus.com/inward/record.url?scp=70350416448&partnerID=8YFLogxK
U2 - 10.1016/j.ejpb.2009.08.009
DO - 10.1016/j.ejpb.2009.08.009
M3 - Article
C2 - 19733660
AN - SCOPUS:70350416448
SN - 0939-6411
VL - 73
SP - 399
EP - 403
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
IS - 3
ER -